Chas­ing a 'mas­ter mod­u­la­tor' in the en­do­cannabi­noid sys­tem, biotech up­start promis­es to shake up neu­ropsy­chi­atric treat­ments

For two years in the ear­ly 2000s, new dis­cov­er­ies and bud­ding en­thu­si­asm around the en­doge­nous cannabi­noid sys­tem — so named be­cause it’s re­spon­si­ble for the ef­fects …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.